T2T 접근법에 따라 류마티스 관절염 환자의 치료 결정을 안내하는 초음파 (US-RA-T2T)
Population
Patients with a diagnosis of Rheumatoid Arthritis (RA), moderate or high clinical disease activity (CDAI>10) despite conventional synthetic (cs)DMARD(s) or bs-ts-DMARDs therapy for ≥3 months, and a maximum of 2 swollen joints (out of 44 joints)
Study design
Randomised multicentre, parallel-arm clinical study
Primary objective
Non-inferiority of the experimental arm (i.e. clinical therapy together with ultrasound guided treatment decision) in comparison to the control arm (clinically guided decision) concerning the proportion of patients reaching low disease activity (CDAI ≤10) and a minimal clinical important improvement (MCII: improvement of ≥6 points if starting from moderate disease activity, any case starting from high disease activity and achieving low disease activity) or remission according to ACR/EULAR index-based remission criteria (CDAI ≤2.8/Boolean remission) at week 24.
Intervention
This is a randomised multicentre, national, parallel-arm clinical study. Patients with a diagnosis of RA, moderate or high clinical disease activity (CDAI>10) despite conventional synthetic (cs)DMARD(s) or b-tsDMARDs therapy for ≥3 months, and a maximum of 2 swollen joints (out of 44 joints) will be included and randomized to one of the following two strategic arms:
- Clinical decision strategy: All patients receive a new course of b-ts-DMARDs, with or without concomitant cDMARD. If a CDAI ≤10 is not achieved after 12 weeks, patients are switched to a bDMARD or tsDMARD. The decision on which b/tsDMARD to use at week 12 is at the discretion of the investigator.
- Clinical plus ultrasound-based decision strategy. All patients in this group will be evaluated by ultrasound at 44 joints. In case of clinically-verified plus ultrasound verified inflammation, patients will receive a new b-ts-DMARD while continuing or not background csDMARD(s) therapy. If a CDAI ≤10 is not achieved after 12 weeks, patients are again evaluated by ultrasound at 44 joints. In case clinically-verified plus ultrasound-verified inflammation is present, patients are switched to a bDMARD or tsDMARD. The decision on which b/tsDMARD to use is at the discretion of the investigator. In case clinically-verified plus ultrasound-verified inflammation is absent, patients receive step-up pain therapy while background treatment will be continued.
Sample size
158 patients
Time plan
- Total duration of the study: 72 months
- Active phase for each patient: 48 weeks (24 weeks for the interventional treatment strategy and 24 weeks for follow-up visit)
- Recruitment: 60 months
연구 개요
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Christian Dejaco, MD, PhD
- 전화번호: +390474581862
- 이메일: Christian.Dejaco@sabes.it
연구 장소
-
-
Bolzano
-
Bruneck, Bolzano, 이탈리아, 39031
- 모병
- Azienda Sanitaria dell'Alto Adige
-
연락하다:
- Christian Dejaco, MD, PhD
- 전화번호: +390474581862
- 이메일: Christian.Dejaco@sabes.it
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Classification of RA according to the ACR-EULAR 2010 criteria
- Age of the patients: 18 to 84 years
- Patients with moderate or high disease activity according to CDAI (>10)
- Maximum of 2 clinically swollen joints out of a 44-joint count
- Current stable treatment with a single csDMARD or bDMARD or tsDMARD for at least 3 months
- No glucocorticoid therapy or stable glucocorticoid dose for at least 4 weeks and at a maximum dose of 5 mg/day prednisone equivalent.
- No corticosteroid intraarticular injection within 4 weeks
- Stable or absent dose of NSAIDs for at least 1 week
- Patients able and willing to give written informed consent and compliant with the requirements of the study protocol
Exclusion Criteria:
- Complete (clinically evident) destruction of any joint to be investigated by ultrasound as judged by the physician
- Current RA-related vasculitis or other active systemic (i.e. extraarticular) RA-manifestation except for rheumatoid nodules, which in the opinion of the investigator would expose the study subject to a high risk of morbidity or mortality
- Initial arthritis manifestations before the age of 18 years
- Planned surgery within the study period for any of the joints investigated either clinically or by sonography
- Current severe medical illness requiring hospitalization
- Active infection or active malignancy at screening <5 years
- Any contraindication to b/ts DMARDs according to the "Summary of Product Characteristics"
- Pregnancy or lactation
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
간섭 없음: Conventional decision strategy
All patients receive a new course of b-ts-DMARDs, with or without concomitant cDMARD. If a CDAI ≤10 is not achieved after 12 weeks, patients are switched to a bDMARD or tsDMARD. The decision on which b/tsDMARD to use at week 12 is at the discretion of the investigator. |
|
|
실험적: Clinical plus ultrasound-based decision strategy
All patients in this group will be evaluated by ultrasound at 44 joints. In case of clinically-verified plus ultrasound verified inflammation, patients will receive a new b-ts-DMARD while continuing or not background csDMARD(s) therapy. If a CDAI ≤10 is not achieved after 12 weeks, patients are again evaluated by ultrasound at 44 joints. In case clinically-verified plus ultrasound-verified inflammation is present, patients are switched to a bDMARD or tsDMARD. The decision on which b/tsDMARD to use is at the discretion of the investigator. In case clinically-verified plus ultrasound-verified inflammation is absent, patients receive step-up pain therapy while background treatment will be continued. |
At baseline and at weeks 12, 24 and 48, patients will undergo an ultrasound examination of 44 joints by one investigator, who is blinded to the strategic arm and all clinical data. The following joints will be assessed: bilateral wrists (distal radio-ulnar joint, radio-carpal, mid-carpal recesses), 1st - 5th MCP, 1st - 5th PIP, elbows, glenohumeral, acromioclavicular, sternoclavicular, knees, ankles and 1st - 5th MTP. At wrists, MCP and PIP joints, palmar and dorsal sites including synovial recess, extensor and flexor tendons will be investigated whereas at feet the dorsal site (plus the lateral aspects of MTP5) including synovial recess and extensor tendons will be evaluated. Further, we will assess the following: at elbows the dorsal and anterior recess, at shoulders the dorsal recess, at knees the suprapatellar as well as the medial and lateral femoro-tibial recess and at ankles the anterior, lateral and medial recess of the tibiotalar joint. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Non-inferiority of ultrasound-based decision strategy compared to clinically-based strategy.
기간: 24 weeks
|
Non-inferiority of the experimental arm (i.e. clinical plus ultrasound-guided treatment decision) in comparison to the control arm (clinically-guided decision) concerning the proportion of patients reaching low disease activity (CDAI ≤10) and a minimal clinical important improvement (MCII: improvement of ≥6 points if starting from moderate disease activity, any case achieving low disease activity who started from high disease activity) [19] or remission according to ACR/EULAR index-based remission criteria (CDAI ≤2.8/Boolean remission) at week 24. |
24 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
12주차와 48주차에 ACR/EULAR 지수 기반 관해 기준에 따른 저질병 활성도와 MCII 또는 관해에 있는 환자의 비율 비교
기간: 12주 및 48주
|
12주 및 48주
|
|
|
12주차, 24주차 및 48주차에 ACR/EULAR 지수 기반 관해 기준(각각 CDAI ≤2.8/Boolean 관해)에 따라 관해된 환자의 비율 비교
기간: 12주, 24주 및 48주
|
12주, 24주 및 48주
|
|
|
12주, 24주 및 48주차에 DAS-28(DAS-28 ≤2.6) 또는 SDAI(≤3.3)에 따른 관해 상태에 있는 환자의 비율 비교
기간: 12주, 24주 및 48주
|
12주, 24주 및 48주
|
|
|
12주, 24주 및 48주차의 부드러운 관절 수치 비교
기간: 12주, 24주 및 48주
|
12주, 24주 및 48주
|
|
|
12주, 24주, 48주차 관절 부종 수치 비교
기간: 12주, 24주 및 48주
|
12주, 24주 및 48주
|
|
|
12주, 24주 및 48주의 적혈구 침강 속도(ESR) 값 비교
기간: 12주, 24주 및 48주
|
12주, 24주 및 48주
|
|
|
12주, 24주 및 48주의 C 반응성 단백질(CRP) 값 비교
기간: 12주, 24주 및 48주
|
12주, 24주 및 48주
|
|
|
24주차와 48주차의 EuroQol-5 차원(EQ5D) 점수 비교
기간: 24주 및 48주
|
24주 및 48주
|
|
|
12주, 24주 및 48주에 PD 점수가 ≤1(44관절 수)인 환자 비교
기간: 12주, 24주 및 48주
|
12주, 24주 및 48주
|
|
|
Comparison of value of VAS (Visual Analogue Scale) pain at weeks 12, 24 and 48
기간: 12, 24 and 48 weeks
|
Range: 0, better outcome - 100, worse outcome |
12, 24 and 48 weeks
|
|
Comparison of value of VAS (Visual Analogue Scale) Patient Global Assessment of Disease Activity at weeks 12, 24 and 48
기간: 12, 24 and 48 weeks
|
Range: 0, better outcome - 100, worse outcome |
12, 24 and 48 weeks
|
|
Comparison of value of VAS (Visual Analogue Scale) Physician Global Assessment of Disease Activity at weeks 12, 24 and 48
기간: 12, 24 and 48 weeks
|
Range: 0, better outcome - 100, worse outcome |
12, 24 and 48 weeks
|
|
Comparison of Health assessment questionnaire (HAQ) score at week 24 and 48
기간: 24 and 48 weeks
|
Range: 0, better outcome - 3, worse outcome |
24 and 48 weeks
|
|
Comparison of Rheumatoid Arthritis Impact of Disease (RAID) score at week 24 and 48
기간: 24 and 48 weeks
|
Range: 0, better outcome - 10, worse outcome |
24 and 48 weeks
|
|
Comparison of Fatigue Assessment Scale (FAS) score at week 24 and 48
기간: 24 and 48 weeks
|
Range: 10, better outcome - 50, worse outcome |
24 and 48 weeks
|
|
Comparison of the trend of VAS (Visual Analogue Scale) pain across all study visits
기간: 48 weeks
|
Absolute and relative change of parameter with respect to the baseline and between different visits |
48 weeks
|
|
Comparison of the trend of VAS (Visual Analogue Scale) Patient Global Assessment of Disease Activity across all study visits
기간: 48 weeks
|
Absolute and relative change of parameter with respect to the baseline and between different visits |
48 weeks
|
|
Comparison of the trend of Health assessment questionnaire (HAQ) score across all study visits
기간: 48 weeks
|
Absolute and relative change of score with respect to the baseline and between different visits |
48 weeks
|
|
Comparison of the trend of Rheumatoid Arthritis Impact of Disease (RAID) score across all study visits
기간: 48 weeks
|
Absolute and relative change of score with respect to the baseline and between different visits |
48 weeks
|
|
Comparison of the trend of Fatigue Assessment Scale (FAS) score across all study visits
기간: 48 weeks
|
Absolute and relative change of score with respect to the baseline and between different visits |
48 weeks
|
|
Comparison of the trend of EuroQol-5 dimensions (EQ5D) score across all study visits
기간: 48 weeks
|
Absolute and relative change of score with respect to the baseline and between different visits |
48 weeks
|
|
Comparison of the differences in the Sharp van der Heijde Score from baseline to week 48
기간: 48 weeks
|
Range: 0, better outcome - 448, worse outcome |
48 weeks
|
|
Comparison of direct medical costs of treatment arms from baseline to week 24 and 48
기간: 24 and 48 weeks
|
Measurement: Incremental cost-effectiveness ratio (ICER) |
24 and 48 weeks
|
|
Analysis regarding predictors of low disease activity or remission at 12, 24 and 48 weeks in patients treated with ≥1bDMARD as compared to those who receive pain therapy
기간: 12, 24 and 48 weeks
|
Investigated predictors: baseline erythrocyte sedimentation rate, baseline C reactive protein, baseline ultrasound score (EULAR-OMERACT combined score) |
12, 24 and 48 weeks
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .